Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study

por Yannan Zhao, Cheng Liu, Yingjian Zhang, Chengcheng Gong, Yi Li, Yizhao Xie, Bingrui Wu, Zhongyi Yang, Biyun Wang
Publicado 2018

A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel

por Chengcheng Gong, Zhongyi Yang, Yifei Sun, Jian Zhang, Chunlei Zheng, Leiping Wang, Yongping Zhang, Jing Xue, Zhifeng Yao, Herong Pan, Biyun Wang, Yingjian Zhang
Publicado 2017

Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases

por Yizhao Xie, Chengcheng Gong, Jian Zhang, Leiping Wang, Jun Cao, Zhonghua Tao, Ting Li, Yannan Zhao, Yi Li, Shihui Hu, Biyun Wang, Xichun Hu
Publicado 2021